retatrutide phase 2 trial type 2 diabetes results 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Phase III retatrutide study demonstrates

Semaglutide (Wegovy, Ozempic) Half-life: ~7 days Dosing: Once weekly subcutaneous injection Profile: Provides steady appetite suppression and glycemic control

DIY dose splitting/dilution: Some patients may use insulin syringes or count clicks on the pen to draw out smaller amounts than the lowest marketed dose, or dilute the drug to create microdoses

We see this with other oral peptides as well, like our popular Orforglipron Tablets, where the convenience factor is a huge draw for certain research models

Its a biological response to an obesogenic environment that didnt exist 100 years ago

Both doses significantly outperformed the placebo across all measured outcomes

Risk allele carriers might not only benefit from the latest generations of GLP1R agonists including dual GLP1R/GIPR agonists, but also from recently developed GLP1R PAMs or Gs/cAMP pathway-biased ligands